Allena Pharmaceuticals, Inc. Current Part of Taxes to Pay

Current Part of Taxes to Pay of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Current Part of Taxes to Pay growth rates and interactive chart.


Highlights and Quick Summary

  • Current Part of Taxes to Pay for the quarter ending June 30, 2017 was $0 (a NaN% decrease compared to previous quarter)
  • Year-over-year quarterly Current Part of Taxes to Pay decreased by NaN%
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Current Part of Taxes to Pay of Allena Pharmaceuticals, Inc.

Most recent Current Part of Taxes to Payof ALNA including historical data for past 10 years.

Interactive Chart of Current Part of Taxes to Pay of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Current Part of Taxes to Pay for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2017 $0.0 $0.0
2016 $0.0
2015 $0.0

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.